{"url_path":"/sec/cvkd/8-k/2026-07-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1937993/0001213900-26-079824-index.html","accession_number":"0001213900-26-079824","cik":"0001937993","ticker":"CVKD","issuer_name":"Cadrenal Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1937993/0001213900-26-079824-index.html","primary_entity_key":"0001937993","primary_entity_name":"Cadrenal Therapeutics, Inc."},"word_count":110,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\nThe\nfollowing exhibits are furnished with this Current Report on Form 8-K:\n\n \n\n**Exhibit\nNumber**\n \n**Exhibit\nDescription**\n\n99.1\n \n[Press Release, issued by Cadrenal Therapeutics, Inc. on July 21, 2026](ea029866901ex99-1.htm)\n\n104\n \nCover Page Interactive\nData File (the cover page XBRL tags are embedded within in the inline XBRL document)\n\n \n\n1\n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDated: July 21, 2026\n**CADRENAL THERAPEUTICS, INC.**\n\n \n \n\n \nBy:\n/s/\nQuang X. Pham\n\n \nName: \nQuang X. Pham\n\n \nTitle:\nChairman and Chief Executive Officer\n\n \n\n2"}